Related Experiment Video
Updated: May 19, 2026
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
Nanoparticles and phage display selected peptides for imaging and therapy of cancer
Cathy S Cutler1, Nripen Chanda, Ravi Shukla
1Research Reactor Center, University of Missouri, Columbia, MO 65211-3400, USA. cutlerc@missouri.edu
Abstract:
Molecular imaging probes are a special class of pharmaceuticals that target specific biochemical signatures associated with disease and allow for noninvasive imaging on the molecular level. Because changes in biochemistry occur before diseases reach an advanced stage, molecular imaging probes make it possible to locate and stage disease, track the effectiveness of drugs, treat disease, monitor response, and select patients to allow for more personalized diagnosis and treatment of disease. Targeting agents radiolabeled with positron emitters are of interest due to their ability to quantitatively measure biodistribution and receptor expression to allow for optimal dose determinations. (68)Ga is a positron emitter, which allows for quantitative imaging through positron emission chromatography (PET). The availability of (68)Ga from a generator and its ability to form stable complexes with a variety of chelates hold promise for expanding PET utilization to facilities unable to afford their own cyclotron. Nanoparticles conjugated with various proteins and peptides derived from phage display that can be selectively targeted are being developed and evaluated for guided imaging and therapy. Herein we highlight some initial efforts in combining the enhanced selectivity of nanoparticles and peptides with (68)Ga for use as molecular imaging probes.
Insights
This study explores novel molecular imaging probes using Gallium-68 (68Ga) and targeted nanoparticles. These probes offer potential for precise disease detection and personalized medicine through advanced positron emission tomography (PET) imaging.
Area of Science:
- Radiochemistry
- Molecular Imaging
- Nanotechnology
Background:
- Molecular imaging probes enable early disease detection and personalized treatment by targeting specific biochemical signatures.
- Positron emitters like Gallium-68 (68Ga) are crucial for quantitative imaging via positron emission tomography (PET).
- The accessibility of 68Ga from generators and its chelation properties facilitate broader PET adoption.
Purpose of the Study:
- To develop and evaluate novel molecular imaging probes by combining Gallium-68 (68Ga) with targeted nanoparticles.
- To leverage the enhanced selectivity of nanoparticles and peptides for improved molecular imaging applications.
- To explore the potential of these combined probes for guided imaging and therapy.
Main Methods:
- Radiolabeling of targeting agents with the positron emitter 68Ga.
- Conjugation of nanoparticles with peptides derived from phage display for targeted delivery.
- Evaluation of the combined nanoparticle-peptide-68Ga constructs for molecular imaging.
Main Results:
- Initial efforts demonstrate the feasibility of combining targeted nanoparticles with 68Ga for molecular imaging.
- The developed probes show promise for enhanced selectivity in targeting disease biomarkers.
- This approach integrates nanoparticle targeting with the quantitative capabilities of 68Ga-PET.
Conclusions:
- Combining targeted nanoparticles with 68Ga represents a promising strategy for developing advanced molecular imaging probes.
- These novel probes have the potential to improve disease diagnosis, staging, and therapeutic monitoring.
- The use of generator-produced 68Ga and nanoparticle targeting could expand the clinical utility of PET imaging.
